Intracervical administration of prostaglandin E2 prior to vacuum aspiration. A prospective double-blind randomized study.
Two-hundred and ninety-three patients without a previous vaginal delivery were randomized to intracervical/extra-amniotic application of 0.5 mg prostaglandin E2 (PGE2) or to gel only. Of the patients who received PGE2, 18.7% were admitted before the next morning due to spontaneous abortion, bleeding or pains. No other side-effect was observed. A statistically significant dilatation of the cervical canal was found in the prostaglandin group. Thirty percent of the treated patients did not need further dilatation of the cervix 25.4% were non-responders to PGE2 and 7.7% were hyper-responders. The number of uterine perforations, pelvic inflammatory disease (PID) or retained pregnancy products were not influenced by the pretreatment with PGE2.
Iversen
T
T
Skjeldestad
F E
FE
D000032:Abortion, Therapeutic / Q000379:methods*; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects; D002986:Clinical Trials as Topic; D004107:Dilatation and Curettage; D015232:Dinoprostone; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D011247:Pregnancy; D011458:Prostaglandins E / Q000008:administration & dosage* / Q000009:adverse effects; D011897:Random Allocation; D014595:Uterine Perforation / Q000209:etiology; D014619:Vacuum Curettage
D011458:Prostaglandins E; D015232:Dinoprostone